Astellas Pharma vs. Apsen: Modified Release Drug Patent Invalidated
Que souhaitez-vous faire ensuite ?
Choisissez votre parcours en fonction de vos besoins actuels :
📋 Résumé de l'affaire
| Nom de l'affaire | Astellas Pharma, Inc. v. Apsen Farmacêutica S/A |
| Numéro de dossier | 2332814-55.2023.8.26.0000/50001 |
| Tribunal | Court of Justice of São Paulo (Tribunal de Justiça do Estado de São Paulo — TJSP) |
| Durée | Closed: April 2, 2024 |
| Résultat | Brevet invalidé |
| Brevets en cause | |
| Produits incriminés | Modified release oral pharmaceutical composition and its manufacturing process |
Aperçu du dossier
Les parties
⚖️ Demandeur
Tokyo-headquartered global pharmaceutical company with a substantial portfolio of branded pharmaceutical products, including formulation-specific patents.
🛡️ Défendeur
Brazilian pharmaceutical manufacturer with a portfolio spanning branded generics and specialty pharmaceuticals, a domestic competitor.
Le brevet en cause
This landmark case involved Brazilian patent BRPI0919466B1 covering a modified release oral pharmaceutical composition and its manufacturing process. Modified release formulations represent a significant class of pharmaceutical intellectual property, governing how active pharmaceutical ingredients are delivered over time within the body. These patents often extend effective market exclusivity beyond the primary compound patent and are frequently targeted in invalidity proceedings.
- • BRPI0919466B1 — Modified release oral pharmaceutical composition and its manufacturing process
Vous développez un produit pharmaceutique similaire ?
Check if your modified release drug formulation might infringe existing or related patents before launch.
Le verdict et l'analyse juridique
Résultat
The Court of Justice of São Paulo closed case No. 2332814-55.2023.8.26.0000/50001 with the **invalidation of patent BRPI0919466B1**. The ruling, finalized on April 2, 2024, came after Apsen Farmacêutica S/A pursued an invalidity and cancellation action, a defense strategy increasingly deployed by Brazilian generic and specialty pharmaceutical manufacturers.
Principales questions juridiques
The operative cause of action was an **invalidity/cancellation action** (ação de nulidade de patente) under Brazilian Industrial Property Law (Law No. 9.279/1996, Article 56). The court’s final ruling addressed appellate objections under **Article 1.025 of Brazil’s CPC**, the pre-questioning provision, affirming the invalidity outcome and declining to reopen substantive questions already resolved.
This decision highlights the vulnerability of formulation patents — even those covering commercially significant modified release technologies — to validity challenges in Brazilian courts, reinforcing the pattern of tribunals applying rigorous patentability standards to pharmaceutical formulation claims.
Analyse de la liberté d'exploitation (FTO)
This case highlights critical IP risks in modified release drug design. Choose your next step:
📋 Comprendre l'impact de cette affaire
Découvrez les risques et les implications spécifiques liés à ce litige.
- View related patents in pharmaceutical formulations
- See which companies are active in modified release technologies
- Understand claim construction patterns in Brazil
🔍 Vérifier les risques liés à mon produit
Effectuez une analyse FTO complète pour votre propre technologie ou produit.
- Saisissez la description de votre produit ou ses caractéristiques techniques.
- L'IA identifie les brevets susceptibles de constituer un obstacle
- Obtenir un rapport d'évaluation des risques exploitable
Zone à haut risque
Secondary pharmaceutical patents (formulation)
Brazilian Law
Rigorous patentability standards
Strategic Challenges
Effective for market access
✅ Points clés à retenir
Brazilian invalidity actions under Article 56, Law 9.279/1996 are powerful offensive tools against pharmaceutical formulation patents.
Rechercher la jurisprudence connexe →Article 1.025 CPC pre-questioning is essential appellate practice for preserving higher court review rights in Brazil.
Explorer les précédents juridiques →Dual composition-and-process patent claims do not guarantee doubled protection — both can fall in a single invalidity action.
Analyser la portée de la réclamation →Appellate courts in São Paulo are applying substantive patentability scrutiny to formulation innovations.
Monitor court trends →Foire aux questions
The case concerned Brazilian patent BRPI0919466B1, covering a modified release oral pharmaceutical composition and its manufacturing process.
The patent was invalidated through an invalidity and cancellation action filed by Apsen Farmacêutica. The specific technical grounds were not disclosed in available case records.
The outcome reinforces that formulation patents — including modified release compositions — are subject to rigorous validity challenges in Brazilian courts, signaling risk for originator companies relying on secondary patents for market exclusivity.
Prêt à renforcer votre stratégie en matière de brevets ?
Rejoignez plus de 18 000 professionnels de la propriété intellectuelle qui utilisent PatSnap Eureka pour effectuer des recherches d'antériorité, rédiger des brevets et analyser le paysage concurrentiel avec une précision optimisée par l'IA.
Références
- Court of Justice of São Paulo (TJSP) — Case No. 2332814-55.2023.8.26.0000/50001
- INPI Brazilian Patent Database
- Brazil’s Industrial Property Law No. 9.279/1996 (Article 56)
- PatSnap — Solutions de veille en matière de propriété intellectuelle pour les cabinets d'avocats
Cet article est publié à titre purement informatif et ne constitue en aucun cas un avis juridique. Toutes les informations relatives aux affaires sont tirées de dossiers judiciaires accessibles au public. Pour en savoir plus sur les fonctionnalités de la plateforme, rendez-vous sur PatSnap.